May 302013
NASDAQ
Data was presented at the 53rd annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) held in the US. ALKS 3831 … Encouraged by the positive results of the phase I study, Alkermes expects to initiate a phase II dose-ranging study on ALKS 3831.http://www.nasdaq.com/article/encouraging-data-from-alkermes-analyst-blog-cm249504
Alkermes plc recently presented encouraging data from a phase I study, which evaluated its schizophrenia candidate, ALKS 3831. Data was presented at the 53rd annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) held in the US. ALKS 3831 is a combination of ALKS 33, and Eli Lilly and Company’ s antipsychotic drug Zyprexa (olanzapine).
Sorry, the comment form is closed at this time.